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Mast cells (MCs) play an important role in allergic hyperresponsiveness and in defend-
ing microorganism infections. Recent studies of experimental animals and humans have
suggested thatMCs participate in obesity and diabetes.MCdistribution and activities in adi-
pose tissues may vary, depending on the locations of different adipose tissues. In addition
to releasing inﬂammatorymediators to affect adipose tissue extracellularmatrix remodeling
and to promote inﬂammatory cell recruitment and proliferation, MCs directly and indirectly
interact and activate adipose tissue cells, including adipocytes and recruited inﬂammatory
cells. Plasma MC protease levels are signiﬁcantly higher in obese patients than in lean
subjects. Experimental obese animals lose body weight after MC inactivation. MC func-
tions in diabetes are even more complicated, and depend on the type of diabetes and on
different diabetic complications. Both plasma MC proteases and MC activation essential
immunoglobulin E levels are signiﬁcant risk factors for human pre-diabetes and diabetes
mellitus. MC stabilization prevents diet-induced diabetes and improves pre-established dia-
betes in experimental animals. MC depletion or inactivation can improve diet-induced type
2 diabetes and some forms of type 1 diabetes, but also can worsen other forms of type 1
diabetes, at least in experimental animals. Observations from animal and human studies
have suggested beneﬁcial effects of treating diabetic patients with MC stabilizers. Some
diabetic patients may beneﬁt from enhancing MC survival and proliferation – hypotheses
that merit detailed basic researches and clinical studies.
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INTRODUCTION
Mast cells (MCs) are inﬂammatory cells similar to macrophages,
neutrophils, and lymphocytes, but they localize near surfaces
exposed to the environment – such as the skin, airway, and gas-
trointestinal tract, where pathogens, allergens, and other environ-
ment agents frequently reside (Metcalfe et al., 1997; Galli et al.,
2005a). These cells therefore are ﬁrst-line immune cells defending
against bacterial and viral infections, and are essential in air-
way hypersensitivity, skin allergies, and food anaphylaxis. Recent
studies, however, suggest that MCs appear in most tested tis-
sues, and are more than just a ﬁrst-line immune response. They
are abundant in tumor tissues (Maltby et al., 2009), in athero-
sclerotic lesions and other vascular lesions (Kovanen, 2007; Sun
et al., 2007a,b), and in inﬂamed white adipose tissue (WAT; Liu
et al., 2009). MCs are derived from hematopoietic progenitor
cells that migrate into virtually any tissue, where they complete
their maturation (Metcalfe et al., 1997). In the microenviron-
ment, MCs require IL3 for early proliferation (Mekori et al.,
1993) and stem cell factor (SCF) from stromal cells to main-
tain viability and maturation (Nocka et al., 1990; Irani et al.,
1992).
Obesity and diabetes are considered chronic inﬂammatory
diseases, largely due to several recent seminal discoveries of inﬂam-
matory cells in WAT – including macrophages (Ochi et al., 1988;
Weisberg et al., 2003; Xu et al., 2003), B cells (Winer et al., 2011),
CD4+ T cells (Winer et al., 2009), CD8+ T cells (Nishimura et al.,
2009), regulatory T cells (Treg; Feuerer et al., 2009), NK T cells
(Ohmura et al., 2010), eosinophils (Wu et al., 2011), and MCs (Liu
et al., 2009). These cells may interact directly through cell–cell
contact, or indirectly by releasing cell mediators within adipose
tissue. Relative to macrophages or lymphocytes, far fewer studies
are available regarding MC functions in obesity and diabetes. This
brief review summarizes what we have learned from experimental
animals and observations from human studies.
MAST CELLS IN OBESITY
Adipose tissue, andWAT in particular, provides structural support
and serves as a reservoir for energy surplus, but it also regulates
metabolism, blood pressure, immune responses, coagulation, and
functions of other endocrine organs (Trayhurn, 2005). A remark-
able heterogeneity exists in the severity of WAT inﬂammation in
different types of fat depots in obese subjects (Murano et al., 2008;
Altintas et al., 2011a).MCs aremyeloid hematopoietic cells derived
from hematopoietic stem cells in the bone marrow. Progenitor
MCs leave the bone marrow and differentiate into different MC
subtypes, corresponding to the tissue compartments into which
they home (Nakano et al., 1985). Recent discoveries demonstrated
that WAT also harbors mast lineage cells that can home to organs
such as intestine and skin,where they fulﬁll their roles (Poglio et al.,
2010). For example, mouse inguinal fat pads contain c-Kit+Thy-
1loLin−Sca+ cells, which can differentiate into other cell types
in vitro, such as functional mucosal MCs (Poglio et al., 2010).
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Therefore, WAT harbors not only MC maturation, but also the
whole process of MC differentiation.
MAST CELLS IN DIFFERENT ADIPOSE TISSUES
WhileWAT fromobese humans and animals contains higher num-
bers of MCs than that from lean subjects in general, MC number,
and functions can vary among fat pads from different locations.
For example, whereas the difference in MC number in subcuta-
neous WAT between obese and lean subjects was not signiﬁcant,
MC numbers in visceral WAT increase signiﬁcantly in obese mice
compared with those in lean mice, and MC crown-like structures
became prevalent in obese visceral WAT (Altintas et al., 2011a).
The infrapatellar fat pad (IFP), also called Hoffa’s fat pad, is an adi-
pose tissue depot located intracapsularly and extrasynovially in the
knee joint, to secrete inﬂammatory cytokines (Tilg and Moschen,
2006; Clockaerts et al., 2010). In a recent study among patients in
the Netherlands, IFPs from patients with osteoarthritis contained
higher amounts of IL6 and adipsin, and higher numbers of MCs,
than those from subcutaneousWAT from the samepatient popula-
tion. IFP TNF-α levels, which may come from MCs, correlate with
body-mass index (BMI) among this osteoarthritis patient popu-
lation (Klein-Wieringa et al., 2011). Unlike subcutaneous WAT or
visceral WAT, epididymal fat masses from mice fed a high-fat diet
(HFD) for 20weeks correlate inversely with body weight and liver
mass. These fat tissues contain abundant dead adipocytes, as well
as MCs, macrophages, and apoptotic cells. Therefore, mouse mast
cell protease-6 (mMCP-6, human tryptase homolog),macrophage
marker F4/80, cell apoptosis marker cleaved caspase-3, and the
levels of the cytokines TNF-α and IL10 mRNA and of protein, all
increased in obese mouse epididymal fat (Altintas et al., 2011b).
Reduced epididymal fat mass in mice with long-standing obesity
therefore is accompanied by divergent distribution of crown-like
structures, apoptotic cells, MCs, and macrophages (Altintas et al.,
2011b).
MAST CELL–T CELL INTERACTIONS IN WAT
White adipose tissue contains CD4+, CD8+, Treg, and NK T cells
(Feuerer et al., 2009; Nishimura et al., 2009; Winer et al., 2009;
Ohmura et al., 2010). We recently showed that CD8+ T cells and
MCs localize together in mouse visceral WAT (Xu and Shi, 2012).
Physical proximity between MCs and T cells proposes a bidirec-
tional functional relationship between the two cell types (Mekori,
2004; Kalesnikoff and Galli, 2008). MCs degranulate in response
to direct contact with T cells or T cell membrane preparations,
and release MC mediators, such as TNF-α, IL8, and oncostatin
M (Baram et al., 2001; Salamon et al., 2008). Separation of the
two cell populations by a semipermeable porous membrane pre-
vents MC activation (Inamura et al., 1998), suggesting that T cells
activate MCs not necessarily by small molecule protein peptides,
but instead by using membrane transfer as a mode in intercel-
lular communication. Many cells, including monocytes (Shi and
Shi, 2010) and T cells (Al-Nedawi et al., 2009; Théry et al., 2009),
release microvesicles. A recent study using Centricon ﬁltration,
high-speed centrifugation, identiﬁcation by electron microscopy,
FACS (Annexin staining), and expression of integrin lymphocyte
function-associated antigen 1 (LFA-1) demonstrated that human
peripheral blood T cells use such microvesicles to activate human
cord blood MC mitogen-activated protein kinase (MAPK) signal-
ing pathway, followed by MC degranulation and release of IL8
and oncostatin M (Sheﬂer et al., 2010). MC activation then boosts
T cell proliferation by MC surface molecule LFA-1 (Sayed and
Brown, 2007; Sheﬂer et al., 2010; Figure 1).
Regulatory T cells inﬂuences the inﬂammatory state of WAT,
thereby increasing insulin sensitivity in mice (Feuerer et al., 2009).
Although there is no direct evidence that Treg interacts with
MCs in WAT, interaction between OX40 on Treg and OX40L on
MCs suppresses MC degranulation and allergic responses (Gri
et al., 2008; Piconese et al., 2009). In vitro interactions between
human and mouse MCs and CD4+CD25+Foxp3+ Treg reduced
FIGURE 1 | Possible interactions between mast cells and inflammatory cells in adipose tissues.
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MC degranulation and Ca2+ mobilization,without affecting over-
all cytokine secretion (Frossi et al., 2011). Anti-OX40L antibody
blocks Treg-mediated MC stabilization (Gri et al., 2008). Treg
also suppress MC expression of high-afﬁnity IgE receptor FcεR1
(Kashyap et al., 2008). Treg may interact with MCs differently,
however, under a different environment. In an allograft toler-
ance model, where MCs are essential in CD4+CD25+Foxp3+
Treg-dependent peripheral tolerance, Treg plays an immunosup-
pressive role by recruiting and activatingMCs.WhenMC-deﬁcient
KitW-sh/W-sh mice do not induce tolerance, Treg produces IL9 to
recruit and activate MCs in tolerant tissues to mediate regional
immunosuppression. Anti-IL9 antibody neutralization leads to
allograft rejection (Lu et al., 2006). In WAT, therefore, whether
Treg activates MCs for immunosuppression or suppresses MC
degranulation remains unknown.
NK T cells participate in WAT inﬂammation. Absence of NK
T cells protects mice from diet-induced obesity (DIO), whereas
NK T cell activation with α-galactosylceramide exacerbates glu-
cose intolerance, macrophage inﬁltration, and WAT inﬂamma-
tory cytokine expression (Ohmura et al., 2010). Although not
tested in WAT, in mice infected with dengue virus, MCs express
chemokine CXCL10 to trigger NK1.1+ cell inﬁltration to dengue
virus-infected footpads – a mechanism of MC control viral infec-
tion within tissues – and limit viral spread to draining lymph
nodes. Recruitment of NK1.1+ cells facilitates viral clearance (St.
John et al., 2011). MCs may control NK T cell inﬁltration to WAT.
We have shown that MC inactivation reduces macrophage inﬁl-
tration to WAT (Liu et al., 2009). MCs also stimulate CD4+ T
cell migration (Kashyap et al., 2008) and proliferation (Kotani
et al., 2007), and enhance antigen-speciﬁc CD8+ T cell activa-
tion and proliferation – a process requiring direct interaction
between MCs and T cells (Stelekati et al., 2009). While CD8+
T cells increased in obese WAT and exhibited adverse effects
in obesity and diabetes (Nishimura et al., 2009), CD4+ T cells
decreased in obese WAT (Winer et al., 2009). Th2 cytokines, such
as IL4 and IL10, reduce the expression of Kit (SCF receptor)
and FcεR1 (Ryan et al., 1998; Mirmonsef et al., 1999) in MCs,
and promote MC apoptosis (Yeatman et al., 2000; Figure 1).
High numbers of Th2 cells and low numbers of MCs therefore
occur in WAT from lean subjects (Liu et al., 2009; Winer et al.,
2009).
MAST CELL–DENDRITIC CELL INTERACTIONS
Dendritic cells (DCs) are the most effective professional antigen-
presenting cells that prime T cells. DCs play an important role
in atherogenesis (Tedgui et al., 2011), but their functions in
obesity and diabetes remain unknown. Several lines of experi-
ments – though most not related to obesity – suggest a con-
troversial role of DCs in inﬂammation. DCs from obese mice
show impaired antigen-presenting activity to activate CD8+ T
cells, due to secretion of immunosuppressive transforming growth
factor-β (TGF-β; Macia et al., 2006; Smith et al., 2009). Murine
peritoneal MCs, however, directly contact immature DCs and
induce their maturation with enhanced expression of DC co-
stimulatory molecules. Co-culture of DCs and MCs releases the T
cell modulating cytokines IFN-γ, IL2, IL6, and TGF-β. MCs also
synergistically increase endotoxin-induced DC secretion of these
cytokines, thereby inducing CD4+ T cell proliferation and the
release of high levels of IFN-γ and IL17. MCs thus may indirectly
promote Th1 and Th17 responses (Dudeck et al., 2011; Figure 1).
In addition to affecting DC maturation, MCs release TNF-α to
mediate DC migration (Suto et al., 2006). In a hapten FITC-
induced cutaneous allergic contact hypersensitivity mouse model,
MC deﬁciency (KitW-sh/W-sh mice) suppressed contact hypersen-
sitivity, which can be repaired by local transfer of MCs from
wild-type (WT)mice,but not those fromTnf−/− MCs. In the same
model, FITC DC migration to draining lymph nodes or airway DC
migration to local lymph nodes are impaired in KitW-sh/W-sh mice
or Tnf−/− mice. In a mouse skin allograft tolerance model, MCs
increased TNF-α-dependent DC accumulation in draining lymph
nodes. MC production of GM-CSF also controls graft-derived DC
survival. DCs that migrate from tolerant allografts to draining
lymph nodes are tolerogenic and can suppress T cell responses
(de Vries et al., 2011). MCs in WAT therefore may also regulate
DC recruitment, maturation, and survival directly and indirectly
(Figure 1). Consistent with this hypothesis, peripheral blood DC
contents are signiﬁcantly higher in obese patients with type 2 dia-
betes than in those without diabetes or lean patients, and DCs
from obese and diabetic patients adhere much more efﬁciently to
coronary smooth muscle cells (SMCs; Musilli et al., 2011).
MAST CELL INTERACTIONS WITH NON-INFLAMMATORY CELLS
Adipocytes, endothelial cells (ECs), and SMCs also are important
components of WAT. We have shown that MCs release inﬂam-
matory cytokines to induce vascular EC and SMC expression of
cysteinyl cathepsins, and therefore may promote angiogenesis and
WAT growth in obese mice (Sun et al., 2007a,b; Liu et al., 2009;
Figure 2). MCs and SMCs express thymic stromal lymphopoi-
etin, which activates MCs to release inﬂammatory cytokines (e.g.,
IFN-γ, TNF-α, and IL1β) and a series of CCL chemokines (Kaur
et al., 2011; Figure 2). Earlier studies showed that nerve growth
factor and cyclooxygenase mediate prostaglandin D2 (PGD) pro-
duction from MCs and T cells, respectively, and that PGD inﬂu-
ences the differentiation of human ﬁbroblasts into adipocytes
(Marshall et al., 1999; Feldon et al., 2006). PGD can be metab-
olized into a ﬁnal metabolite 15-deoxy-delta-12, 14-prostaglandin
J2 (15-deoxy-delta PGJ2), which is a major endogenous ligand
of peroxisome proliferator-activated receptor-γ (PPARγ; Kliewer
et al., 1995;Herlong and Scott, 2006). Recent studies demonstrated
that MC supernatant contains 15-deoxy-delta PGJ2 that induces
pre-adipocyte 3T3-L1 cell adipogenesis (Figure 2). The spe-
ciﬁc PPARγ antagonist GW9662 blocks this MC activity (Tanaka
et al., 2011). Using MC-deﬁcient KitW/Wv mice, the investiga-
tors showed that reduced body weight in KitW/Wv mice can be
reversed by WT bone marrow-derived mast cell (BMMC) trans-
plantation,but not by transplantation of BMMC fromhematopoi-
etic PGD synthase (H-PGDS)-deﬁcient mice. H-PGDS-deﬁcient
BMMC also failed to induce 3T3-L1 differentiation (Tanaka et al.,
2011).
ROLE OF MAST CELLS IN EXPERIMENTAL OBESE ANIMALS
Increased inﬂammation and MC inﬁltration in obeseWAT suggest
an essential role of MCs in obesity and its associated complica-
tions. As discussed earlier, MCs may interact with inﬂammatory
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FIGURE 2 | Possible interactions between mast cells and non-inflammatory cells in adipose tissues.
and non-inﬂammatory cells by direct cell–cell contact or by
releasing inﬂammatory mediators. TNF-α, for example, is an
important mediator of MCs (Zhang et al., 2011a,b) and is
increased in obese rodents. Neutralization of TNF-α with a sol-
uble TNF-α receptor-immunoglobulin G chimeric protein ame-
liorated insulin resistance (Hotamisligil et al., 1993), and obese
mice lacking TNF-α demonstrated improved insulin sensitiv-
ity (Uysal et al., 1997). Hypoadiponectinemia associates with
obesity and insulin resistance (Weyer et al., 2001). Adiponectin
mRNA levels were increased in WAT from MC-null mice fed
an HFD, although serum levels did not change (Tanaka et al.,
2011).
Using KitW-sh/W-sh and KitW/Wv mice, we (Liu et al., 2009)
and others (Tanaka et al., 2011) proved that MCs participate
directly in obesity. While WT mice became obese after consum-
ing an HFD, KitW-sh/W-sh and KitW/Wv mice were protected from
DIO. Adoptive transfer of BMMC from WT or Tnf−/− mice, but
not those from Il6−/−, Ifng−/−, or H-PGDS-deﬁcient mice, par-
tially reversed body weight gain in KitW-sh/W-sh and KitW/Wv mice.
Pharmacological MC inactivation using cromolyn and ketotifen,
two common MC stabilizers, yielded similar results. Both drugs
not only prevented WT mice from DIO, but also reduced pre-
established obesity (Liu et al., 2009), revealing a possible therapy
for obese humans.
MAST CELL-DERIVED MOLECULES IN OBESE PATIENTS
The role of MCs in human obesity has not been examined, but
epidemiological studies consistently have shown a positive asso-
ciation between obesity and the risk of asthma (Beuther, 2009;
Shore, 2010), and low-grade inﬂammation associated with obesity
could be a pathogenetic mechanism linking obesity to asthma
(Hersoug and Linneberg, 2007). In a Danish study, serum MC
tryptase levels, skin prick test reactivity (atopy), methacholine
bronchial hyperresponsiveness (BHR), BMI, and serum lipid lev-
els were determined in 1216 patients. Serum tryptase levels were
much higher in obese patients (BMI> 30) than in lean patients
[BMI< 25; 4.4 (3.0–6.1; 25th–75th percentile)μg/L vs. 3.3 (2.3–
4.9; 25th–75th percentile)μg/L, P < 0.0001]. Among this popu-
lation, serum tryptase levels associated positively with male sex
and smoking, and inversely with alcohol consumption. Tryptase
levels, however, did not associate with atopy or BHR but posi-
tively associated with the symptoms of allergic respiratory disease
and obesity (OR= 1.98, 95% CI= 1.25–3.14). Increasing BMI
therefore associates with serum tryptase levels and the preva-
lence of allergic respiratory disease symptoms, and MC activity
did not affect the association between BMI and asthma and
rhinitis symptoms (Fenger et al., 2011). Similar conclusions were
made in a Spanish study of 420 patients. Among those patients,
serum tryptase associated positively with age and serum IgE lev-
els, but inversely with female sex and heavy alcohol use. Tryptase
levels appear signiﬁcantly higher in non-atopic patients, over-
weight patients, or patients with metabolic syndromes, compared
with those were atopic, of normal weight, or without metabolic
syndrome.
In a multivariate analysis, the signiﬁcance of metabolic syn-
drome association with tryptase levels dropped from P = 0.08 to
P = 0.008 after adjusting for age, sex, atopy status, IgE, alcohol
use, and smoking (Gonzalez-Quintela et al., 2010). These human
studies strongly suggest a role of MC activation in obesity, but this
hypothesis has not been tested directly.
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ROLE OF MAST CELLS IN DIABETES AND DIABETIC
COMPLICATIONS
MAST CELLS IN TYPE 2 DIABETES
We ﬁrst reported that MCs participate directly in type 2 diabetes
mellitus (T2DM). DIO mice also developed glucose intolerance
and insulin resistance, which did not appear in KitW-sh/W-sh and
KitW/Wv MC-deﬁcient mice. MC stabilization with either cro-
molyn or ketotifen had results similar to those from MC-deﬁcient
mice. Genetic deﬁciency and pharmacological inactivation of MCs
therefore prevented diet-induced T2DM in mice (Liu et al., 2009).
Mechanistically, we found that MC-derived IL6 and IFN-γ were
critical to both obesity and diabetes. Reduced T2DM symptoms
(serum glucose, leptin, insulin levels, and glucose tolerance and
insulin sensitivity) in MC-deﬁcient mice can be reversed partially
by adoptive transfer of BMMC from WT or Tnf−/− mice, but
not those from Il6−/− and Ifng−/− mice. But different mecha-
nisms may exist – for example, long-term culture in high-glucose
medium augments IgE-induced MC activation (Anderson et al.,
2010). Although not tested in our study,MC activation may be ele-
vated inDIOmice. Themost important ﬁnding of our study is that
MC stabilization with cromolyn or ketotifen improved glucose
tolerance and insulin sensitivity in DIO mice with pre-established
T2DM. This ﬁnding has been conﬁrmed in a patient with T2DM;
less than 6months of treatment with cromolyn reduced both
plasma glucose and hemoglobin A1c levels to normal ranges (Shi,
personal communication).
MAST CELLS IN TYPE 1 DIABETES
AlthoughMC function in human type 1 diabetesmellitus (T1DM)
has not been studied, several animal models have demonstrated
rather complicated roles of MCs in T1DM. While accumulation
of MCs is detrimental in animals with some T1DM models, MC
depletion is an important mechanism of T1DM development in
different experimental models.
Intravenous administration of alloxan induces T1DM in rats.
These animals show decreased microvascular responses to inﬂam-
matory histamine (Fortes et al., 1983), decreased leukocyte–EC
interaction (Fortes et al., 1991), and reduced MC degranulation
(de Oliveira Barreto et al., 2003; Cavalher-Machado et al., 2004),
but increased leukocyte apoptosis (Otton et al., 2004). These dia-
betic rats therefore are refractory to systemic anaphylactic shock,
and show a selective reduction in the number of pleural MCs – a
phenomenon also observed after treatment with the alternative
diabetogenic agent streptozotocin (STZ; Diaz et al., 1996). Dia-
betic sensitized animals are clearly resistant to local and systemic
allergic inﬂammatory responses (Carvalho et al., 2005). It was
hypothesized that autoimmune T1DM is Th1-dependent and that
allergic responses are Th2-dependent. The susceptibility to one
disease might lead to refractoriness to the other (Huang, 1999).
Children with T1DM and their siblings, therefore, are partially
protected against asthma (Douek et al., 1999), but several stud-
ies suggest that this refractoriness associates with MC depletion
or the inability to activate MCs, and overexpression of endoge-
nous corticosteroids (Diaz et al., 1997; Carvalho et al., 2003). MC
depletion in the intestinal tissue is important in the refractoriness
of diabetic rats to anaphylactic shock. In alloxan-treated rats, oval-
bumin (OVA) sensitization reduces total cell yield in lavage ﬂuid
after antigen challenge (Vianna and Garcia-Leme, 1995). In the
same experimental model, bronchial segments from diabetic rats
showed reduced contraction toOVA,and accompaniedwith a 50%
reduction in degranulated MCs and histamine release, in addition
to changes in MC ultrastructure (Ozsoy and Gül, 2005). Diabetes
also inﬂuences immune cell production of IgE. Total and antigen-
speciﬁc IgE augmentation was suppressed in diabetic sensitized
rats (Carvalho et al., 2003). After transfer of spleen and lymph
node immune cells from naïve mice to diabetic mice, immune
cells lose their ability to form IgE. In contrast, immune cells from
diabetic mice regain their ability to generate IgE after transfer to
non-diabetic recipients (Ptak et al., 1983), suggesting that some
factor(s) in the blood of diabetic mice affect immune cell IgE
production. Diabetes also directly affects MC activities. Rats with
alloxan-induced diabetes mount weaker allergen-evoked pleural
MC degranulation and plasma leakage paralleled with reduction
of MCs in the pleural cavity. Transfer of MCs from sensitized non-
diabetic rats can restore allergen-evoked pleural protein extrava-
sation in diabetic rats. In contrast, transfer of MCs from sensitized
diabetic rats to naïve rats leads to a lower allergen-induced protein
exudation. In vitro, puriﬁed MCs from diabetic rats are hypore-
sponsive to antigen and C48/80 stimulation (de Oliveira Barreto
et al., 2003; Figure 3A).
Alloxan administration induces glucocorticoid overexpression,
which induces MC depletion in the skin, lungs, and intestines
(Pipkorn et al., 1989; Goldsmith et al., 1990; Finotto et al.,
1997). MC depletion and increased endogenous glucocorticoids
are closely related (Diaz et al., 1997). Glucocorticoids exhibit
FIGURE 3 | Mast cells in alloxan-induced type 1 diabetes mellitus. (A)
Alloxan induces type 1 diabetes and suppresses mast cell activities. (B)
Insulin therapy improves mast cell activities in alloxan-induced type 1
diabetes mellitus.
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anti-inﬂammatory activity by inhibiting tissue cytokine and SCF
expression (Schleimer, 1993; Finotto et al., 1997), therefore par-
ticipating in MC depletion in the intestines and other organs in
diabetic rats (Pipkorn et al., 1989; Goldsmith et al., 1990; Finotto
et al., 1997). Treatment with steroid receptor agonist RU486 (Car-
valho Vde et al., 2009) or surgical bilateral adrenalectomy (Diaz
et al., 2001) increases intestinal MC numbers and IL3 staining
and IgE formation in diabetic mice – suggesting a negative corre-
lation between MC–IgE system and serum glucocorticoid levels.
Glucocorticoids also inhibit insulin secretion effectively through
pancreatic β cells (Ludvik et al., 1993), and insulin treatment in
alloxanated rats impairs the increase of systemic corticosterone. A
balance between glucocorticoid and insulin is essential to T1DM
(Diaz et al., 2001; Figure 3A).
Insulin therapy not only suppresses glucocorticoid secretion,
but also stimulates several MC signaling pathways, including Lyn,
Syk, Fyn, adapter protein Gab2, Akt, JNK, p38 kinase, SHIP1, and
protein kinase C-θ. Antigen and insulin or insulin-like growth
factor-1 (IGF-1) synergistically increased antigen-induced MC
degranulation and cytoskeletal rearrangement and promoted MC
survival in the absence of IL3 (Lessmann et al., 2006; Kettner et al.,
2010). In diabetic rats, subcutaneous administration of insulin
revealed an important role of insulin in MC extracellular matrix
protein (ECM; e.g., laminin, ﬁbronectin, and collagen) expression
and MC recruitment (de F Carvalho et al., 2008; Figure 3B). MCs
express integrin-type ECM receptors to mediate their activation
and increase responses to antigen stimulation (Kitaura et al., 2005).
Interaction between MCs and ECM is important to MC migra-
tion and distribution in tissues (Hamawy et al., 1994). Insulin
treatment reverses alloxan-induced reductions in MC numbers,
histamine production, and IgE release (Vianna and Garcia-Leme,
1995; Cavalher-Machado et al., 2004).
The role of MCs in T1DM can also vary by T1DM models. In
3-week-old rats with STZ-induced diabetes, the disease associates
with increased mesenteric vessel ﬁbrosis and MC numbers. Both
mesenteric vessel ﬁbrosis and chymase-positive MC numbers were
reduced after rats received tranilast (Jones et al., 2004), suggesting a
causative role of MCs in STZ-induced diabetes. Biobreeding (BB)
rats and non-obese diabetic (NOD) mice spontaneously develop
autoimmune T1DM (Kikutani and Makino, 1992; Wallis et al.,
2009). DRlyp/lyp rats also develop spontaneous T1DM. Unless
insulin is administered, death follows after T1DM onset as a result
of hyperglycemia and ketoacidosis (Mordes et al., 1996). InBB rats,
islet β cells express eotaxin (Geoffrey et al., 2006), which leads to
inﬁltration of CCR3-expressing neutrophils and MCs to the pan-
creatic islets (Kukreja and Maclaren, 1999; Hessner et al., 2004).
Treatment of DRlyp/lyp rats with cromolyn signiﬁcantly delayed
onset of T1DM relative to saline-treated control rats (Kukreja
and Maclaren, 1999; Geoffrey et al., 2006). Mechanistically, MCs
present antigens to activate T cells in major histocompatibility
complex class I and class II pathways in rodents and humans
(Frandji et al., 1993). T cells are primary mediators of human
and rodent T1DM (Green et al., 1998; Mathis et al., 2001; Groen
et al., 2003). In NOD mice and BB rats, early thymectomy pre-
vents T1DM (Green et al., 1998; Mathis et al., 2001; Groen et al.,
2003). MCs also promote T cell migration to inﬂammatory sites
by producing chemokines or indirectly by increasing EC adhesion
molecule expression (Galli et al., 2005b; Zhang et al., 2011b). As
discussed earlier, MCs also affect DC maturation, migration, and
activity, providing another pathway for T cell activation (Galli
et al., 2005b; Figure 4). In NOD mice, however, anti-FcεR1 anti-
body delayed T1DM onset. Anti-FcεR1 was proposed to activate
basophil and MC release of IL4 and histamine. Anti-FcεR1 anti-
body lost its ability to delay T1DM in Il4−/− NOD mice, but this
ability was not affected by histamine receptor blocker. Basophils,
therefore, were proposed to play a role in T1DM in NOD mice
(Hübner et al., 2011).
MC FUNCTIONS IN DIABETIC COMPLICATIONS
Long-term diabetes associates with numerous complications,
including nephropathy (Fowler, 2008) – a multistage clinical
syndrome characterized by thickening of the glomerular base-
ment membrane and mesangial expansion, with progression into
glomerulosclerosis, tubular necrosis, and interstitial ﬁbrosis, ulti-
mately resulting in renal failure (Wolf and Ziyadeh, 1999, 2007).
MCs are most abundant in the kidneys of diabetic patients with
nephropathy (Okon and Stachura, 2007).An increase in renalMCs
associates with ﬁbrosis and ECM accumulation in the kidneys
FIGURE 4 | Mast cell activities in streptozotocin-induced and spontaneous type 1 diabetes mellitus.
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of diabetic nephropathy patients (Rüger et al., 1996). In kid-
neys from glomerulonephritis patients, MCs are clustered with
T cells and macrophages in the interstitial (not in the glomerulus)
and associate with α-SMA-positive interstitium and percentage
of the interstitial ﬁbrotic areas, suggesting a role of MCs in renal
ﬁbroproliferation and interstitial ﬁbrosis (Tóth et al., 1999).
Mast cells produce TGF-β (Metcalfe, 2008), chymase, tryptase,
cathepsin G, renin (Silver et al., 2004), and TNF-α (Bissonnette
et al., 1995), as summarized in Figure 5. TGF-β is a ﬁbro-
genic cytokine linked to diabetic nephropathy in both animals
and humans (Bollineni and Reddi, 1993; Sato et al., 1998). Ele-
vated TGF-β has been implicated in the pathogenesis of diabetic
nephropathy (Goldfarb and Ziyadeh, 2001). Treatment with an
anti-TGF-β antibody (1D11; Benigni et al., 2006) or a soluble
TGF-β type II receptor (aTβRII.Fc; Russo et al., 2007) reduced
proteinuria, inhibited renal ﬁbrosis, and produced renoprotective
effects in rats with diabetic nephropathy. MC proteases contribute
to renal ﬁbrosis directly or indirectly. In diabetic nephropathy
patients, MC chymase increases and associates with glomeru-
losclerosis, tubulointerstitial ﬁbrosis, and vascular ﬁbrosis (Ritz,
2003; Huang et al., 2007). MC chymase and cathepsin G convert
angiotensin (Ang)-I to Ang-II, thereby activating TGF-β (Met-
calfe et al., 1997; Doggrell and Wanstall, 2005; Helske et al.,
2006). MC chymase and cathepsin G also activate MMP-9 (Ishida
et al., 2008) to promote TGF-β signaling (Wilson et al., 2009).
MC tryptase participates in the development of renal interstitial
ﬁbrosis by increasing ECM production (Kondo et al., 2001). MCs
release histamine and tryptase to differentiate ﬁbroblasts into α-
smooth muscle actin-positive myoﬁbroblasts (Gailit et al., 2001).
In vitro, treatment of rat cardiac ﬁbroblasts with MC tryptase
induced ﬁbroblast proliferation and collagen synthesis (Levick
et al., 2009). Renin, also known as angiotensinogenase, converts
angiotensinogen into Ang-I and regulates TGF-β expression in
rat kidney mesangial cells, independent of Ang-II (Huang et al.,
2007). Patients with diabetic nephropathy have elevated renin lev-
els (Deinum et al., 1999). The renin inhibitor aliskiren attenuates
glomerulosclerosis in diabetic transgenic (mRen-2) 27 rats with
advanced diabetic nephropathy (Kelly et al., 2007). MC hista-
mine stimulates H2 receptor-mediated release of renin from rat
kidneys (Schwertschlag and Hackenthal, 1982), indirectly affects
renal Ang-II production, and induces diabetic nephropathy. TNF-
α expression increases in the glomeruli of rats and humans with
diabetic nephropathy (Nakamura et al., 1993; Mahmoud et al.,
2004). TNF-α overexpression induces renal hypertrophy (Navarro
et al., 2003) and microalbuminuria (Kalantarinia et al., 2003) in
rats with diabetic nephropathy. The TNF-α agonist TNFR:Fc pre-
vents renal hypertrophy (Navarro et al., 2003). The soluble TNF-α
receptor inﬂiximab reduced urine albumin excretion in rats with
diabetic nephropathy (Moriwaki et al., 2007).
MAST CELL PROTEASES AND IGE IN DIABETIC PATIENTS
Although MC functions in T1DM can be complicated, we antic-
ipate a detrimental role of MCs in T2DM, based on our prior
animal studies (Liu et al., 2009). Patients with T2DM are expected
to have increased levels of plasma biomarkers of MC proteases
and associated activation markers. We tested this hypothesis in
our recent community screening study (Wang et al., 2012). In
this study, we screened 3163 volunteers 55–75 years of age, from
three neighborhood communities in Zhejiang Province, China.
Of those, 1197 accepted the invitation for fasting plasma glucose
(FPG) and 2-h oral glucose tolerance test (2 h-OGTT). Among the
subjects, 807 had normal glucose tolerance (FPG< 5.6mmol/L,
2 h-OGTT< 7.8mmol/L), 267 had pre-diabetes (FPG≥ 5.6 and
<7.0mmol/L or 2 h-OGTT≥ 7.8 and <11.1mmol/L), and 123
had T2DM (FPG≥ 7.0mmol/L or 2 h-OGTT≥ 11.1mmol/L).
The Kruskal–Wallis test revealed signiﬁcant differences in plasma
IgE levels among patients with different glucose tolerance status
(P = 0.008). A linear regression test showed signiﬁcant correla-
tions between plasma chymase (P = 0.030) and IgE (P = 0.022)
and diabetes mellitus. Ordinal logistic regression analysis demon-
strated that IgE was a signiﬁcant risk factor of pre-diabetes and
T2DM before (odds ratio: 1.674, P = 0.034) or after adjustment
FIGURE 5 | Mast cell functions in diabetic nephropathy.
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(odds ratio: 1.866, P = 0.015) of all tested T2DM risk factors.
Although not statistically signiﬁcant, plasma tryptase levels were
also higher in T2DM patients than in those with pre-diabetes or
with normal glucose levels (Wang et al., 2012). More sophisticated
studies are required to test a role of MCs in diabetes or obesity, but
this human study inspired us to explore MC participation in these
metabolic diseases.
PERSPECTIVE
Observations from experimental animals and diabetic patients
strongly suggest a direct participation of MCs in both obesity
and diabetes, although the mechanisms by which MCs contribute
to the pathogenesis of these metabolic diseases are rather com-
plicated. Our animal study, using both cromolyn and ketotifen
to treat pre-established obesity and T2DM in mice, encouraged
us to develop novel medications for patients with those meta-
bolic diseases by inactivating MCs. Indeed, in an early study
to evaluate cromolyn applications in asthma patients, stabiliza-
tion with a cromolyn nasal spray reduced body weight by more
than 3 pounds in less than 3months (Clarke and May, 1980).
But other potential actions of cromolyn are unknown; reduced
body weight (Clarke and May, 1980) or improved T2DM (Shi,
personal communication) in humans do not necessarily relate
only to MCs. Tranilast, for example, was developed as a MC
stabilizer (Koda et al., 1985), and it reduces tubulointerstitial
ﬁbrosis, tubular atrophy, and albuminuria in rats with diabetic
nephropathy (Mifsud et al., 2003) and retards the progression of
advanced diabetic nephropathy in humans (Soma et al., 2002).
But these tranilast activities may not result from MC stabilization
only. In STZ-treated diabetic rats, tranilast reduced mesenteric
weight, superior mesenteric artery wall-to-lumen ratio, matrix
deposition, and expression of TGF-β, epidermal growth factor
(EGF), and collagens – therefore attenuating vascular hypertrophy
(Bonnet et al., 2003). In these mice, both ECs and MCs express
endothelin, which constricts blood vessels. The endothelinA/B
receptor antagonist bosentan had the same effects as tranilast,
but bosentan did not prevent TGF-β overexpression in dia-
betic rats (Gilbert et al., 2000). Tranilast, therefore, may target
cells other than MCs – such as ECs. Indeed, tranilast inhibits
EC protein kinase C and nuclear factor-κB activities (Koyama
et al., 1999; Spiecker et al., 2002). Tranilast also inhibits TGF-
β release from ﬁbroblasts and monocytes/macrophages (Suzawa
et al., 1992; Yamada et al., 1994), and suppresses insulin secretion
and induces glucose uptake from glucose-induced rat islets and
a tolbutamide-treated rat islet cell line (INS-1E) without affect-
ing their glucose transporter (Glut2) expression (Taguchi et al.,
2008). We showed that MCs release inﬂammatory cytokines to
induce EC adhesion molecule expression (Zhang et al., 2011b).
MCs also interact with macrophages and induce expression of
prostaglandin E2 and 6-keto-prostaglandin F1 during immedi-
ate hypersensitivity reactions (Jakschik et al., 1987). Tranilast
activities, therefore, may associate indirectly with MC activ-
ity inhibition. More basic and clinical studies in this ﬁeld
will beneﬁt greatly to patients suffering from these social dis-
eases.
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